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ZHENG is the key theory in traditional Chinese medicine (TCM) and it is very important to ﬁnd the molecular pharmacology
of traditional Chinese herbal formulae. One ZHENG is related to many diseases and the herbal formulae are aiming to ZHENG.
Therefore, many herbal formulae whose eﬀects on a certain disease have been conﬁrmed might also treat other diseases with
the same ZHENG. In this study, the microarrays collected from patients with QiXuXueYu ZHENG (Qi-deﬁciency and Blood-
stasis syndrome) before treatment and after being treated with Fuzheng Huayu Capsule were analyzed by a high-throughput
gene microarrays-based drug similarity comparison method, which could ﬁnd the small molecules which had similar eﬀects with
Fuzheng Huayu Capsule. Besides getting the results of anti-inﬂammatory and anti-ﬁbrosis drugs which embody the known eﬀect
of Fuzheng Huayu Capsule, many other small molecules were screened out and could reﬂect other types of eﬀects of this formula
in treating QiXuXueYu ZHENG, including anti-hyperglycemic, anti-hyperlipidemic, hyposenstive eﬀect. Then we integrated this
information to display the eﬀect of Fuzheng Huayu Capsule and its potential multiple-target molecular pharmacology. Moreover,
through using clinical blood-tested data to verify our prediction, Fuzheng Huayu Capsule was proved to have eﬀects on diabetes
and dyslipidemia.
1.Introduction
The traditional Chinese medicine (TCM) ZHENG, also
known as TCM syndrome, is the key theory in TCM and the
important diagnostic principle for TCM therapy [1]. It is
very important to describe ZHENG in molecular level or
ﬁnd the molecular marks in ZHENG identiﬁcation or classi-
ﬁcation, and then ﬁnd the molecular pharmacology of
traditional Chinese herbal formulae whose treatment are
based the ZHENG.
Most current researches in ZHENG and herbal formulae
were guided by the theory of western medicine, their study
objects are “disease,” not “ZHENG.” So these researchers had
got a certain “disease,” and did some ZHENG identiﬁcation
and ZHENG classiﬁcation work based on that certain disease
[2, 3], though using high-throughput gene microarrays.
Similarly, most researches in herbal formulae were limited to
ﬁndthe evidence ofherbal formulae’s eﬀectson some certain
“diseases” [4–8].
As we know, Chinese herbal formulae should aim to
“ZHENG,” not to “disease.” Li et al. [9–11]h a dd e s i g n e d
some systemic network method using public disease and
drug component information to analyze the complexity of
ZHENG and herbal formulae. For example, they had divided
many diseases into cold ZHENG and hot ZHENG.
Since one ZHENG could relate many diseases and herbal
formulae aimed to ZHENG, many herbal formulae, whose
eﬀect on a certain disease had been conﬁrmed, might also
treat other diseases with the same ZHENG (Figure 1).
In order to prove this idea, high-throughput gene mi-
croarrays were analyzed. The microarrays were collected
from patients with QiXuXueYu ZHENG (Qi-deﬁciency and2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Prediction of herbal formulae’s new treatment with
the theory of “same ZHENG in diﬀerent diseases.” Many herbal
formulae, whose eﬀect on a certain disease had been conﬁrmed,
might also treat other diseases with the same ZHENG.
Blood-stasis syndrome) before treatment and treated with
Fuzheng Huayu Capsule by a high-throughput drug sim-
ilarity comparison method, we called it pathway-based
similarity comparison (PBSC).
QiX uX ueY uisaZHENGwhosepatientssuﬀerimportant
energy deﬁciency and blood stasis. It is related with many
diﬀerent diseases such as diabetes mellitus [12, 13], dyslipi-
demia [14], hypertension [15], hepatitis, and liver cirrhosis
[16]. This phenomenon is called “Same ZHENG in diﬀerent
diseases.” Fuzheng Huayu Capsule is a recipe on the basis of
Chinese medicine theory in treating liver ﬁbrosis [17]w i t h
QiXuXueYu ZHENG, but few researches had been done to
ﬁnd its treatment on other diseases above.
The PBSC method was based on a microarray database
“Connectivity Map” (cMap) [18], which collect microarrays
corresponding to treatment of 164 diﬀerent small molecules
in diﬀerent human cell lines. In association with the cMap,
a lot of groups explored its usage in various applications,
including drug resistance analysis [19], and toxicity predic-
tion [20], But no one used this data resource to predict new
treatment of Chinese herbal formulae.
We ﬁrst apply the cMap database consistent with high-
throughput expression data to predict new treatment of
Chinese herbal formulae. In our results, there were many
drug molecules screened out, including antihyperglycemic,
antihyperlipidemic, hypotensive, anti-inﬂammatory, and
antiﬁbrosis drugs and some molecules having global eﬀects.
By integrating all the molecules’ information, a Fuzheng
Huayu Capsule mechanism map was obtained and Fuzheng
Huayu Capsule had both short-term treatment eﬀect and
long-term prevention and healthcare eﬀect. Furthermore,
clinical blood-tested data were used to verify our prediction
and ﬁnding that Fuzheng Huayu Capsule can really relieve
the patients suﬀering liver cirrhosis combined with diabetes
mellitus or dyslipidemia.
2.MaterialandMethods
2.1. Samples. There were six blood samples, in which
four samples were from two QiXuXueYu ZHENG patients
(patients A and B) in both states of before treatment and
being treated with Fuzheng Huayu Capsule (3200mg ∗
3times/day, 24 weeks). The rest two samples were from
QiXuXueYu ZHENG patients (patient C) in both states of
beforetreatmentandbeingtreatedwithplacebo(vehicle).All
patients were suﬀering liver cirrhosis from Shanghai Long-
hua Hospital and had signed an agreement with us. The
blood samples were morning fasting venous blood and saved
in −20◦C with 150μL EDTA.
Except for the 6 samples, there were additional 360
blood samples from 180 QiXuXueYu ZHENG patients with
in both states of before treatment and being treated with
Fuzheng Huayu Capsule, and blood tests were taken from
these samples to verify our prediction. All the 180 patients
were suﬀering liver cirrhosis. But these samples were at
ﬁrst not collected to prove the eﬀect of Fuzheng Huayu
Capsule on hyperglycemia or dyslipidemia, so the samples
of patients suﬀering liver cirrhosis combining hyperglycemia
or dyslipidemia were not very abundant. Seventeen patients
had higher fasting blood-glucose (GLU), 31 patients had
higher postprandial blood sugar (PPG), and 21 patients had
higher glycated hemoglobin (Hb1Ac). Fifteen patients’ total
cholesterols (T-ch) were abnormal. Among them, 7 patients
had higher T-ch than the normal range, while 8 patients had
lower T-ch than the normal range. Eighteen patients’ Total
triglycerides (TGs) were abnormal. Among them, 11 patients
had higher T-ch than the normal range, while 7 patients had
lower T-ch than the normal range.
2.2. RNA Extraction and Microarrays. The TRIzol reagent
(Invitrogen Life Technologies Company) was used to extract
RNA of leukocyte from the whole blood of the 6 samples,
then did a Quality Control with NanoDrop ND-1000.
cDNA was obtained through the Invitrogen ﬁrst-strand
cDNA synthesis using M-MLV RT and added RNA poly-
merase to degrade RNA. cDNA labelling and hybridizations
onNimbleGenHomosapiens12 ×135KArray(Roche,CAT
No. A6484-00-01) were performed according to the manu-
facturer’s protocol.
2.3. Microarray Data Analysis. Microarray data analysis was
performed using the GenePix software. Raw expression data
were log2-transformed and normalized by quantile nor-
malization. Probes were considered robustly expressed if
signal/noise ratio (SNR) < 2.
2.4.ConnectivityMap(cMap)Database. “ConnectivityMap”
is a reference collection of gene-expression proﬁles from
cultured human cells treated with bioactive small mol-ecules
or drug molecules [18]. The data set was composed of
mRNA expression data for 164 distinct small-mol-ecules
and corresponding vehicle controls applied to human cell
lines. All these data were by means of Aﬀymetrix Gen-
eChip microarrays. We had downloaded total of 564 gene
expression proﬁles, representing 453 individual instances at
http://www.broad.mit.edu/cmap/.
2.5. Pathway Set. Gene sets were needed to sort out genes
according to meaningful signal pathways. A set called
Sigpathway [21] was used in our method. These gene setsEvidence-Based Complementary and Alternative Medicine 3
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Figure 2: The process of PBSC method. 2-fold change was used as
thresholdfor diﬀerential expression, and then Gene Set Enrichment
Analysis (GSEA) was performed in every pathway. pathways, whose
P-values obtained from GSEA was smaller than 0.05, were selected.
Based on the selected Pathways, the expression pattern similarity
between the microarrays of ours and in the cMap Database in every
pathway was calculated using the KS-test.
are an integration of diﬀerent pathway databases, including
Biocarta, KEGG, BioCyc, pathway-speciﬁc microar-ray
annotations, and >5,000 gene sets from Gene Ontology. The
Sigpathway was available as an R package on http://www.
bioconductor.org/packages/devel/bioc/html/sigPathway.
html.
2.6. Pathway-Based Similarity Comparison (PBSC) Method.
The process of PBSC was showed in Figure 2. At ﬁrst 2-fold
change was used as threshold for diﬀerential expression in
every sample pair (treated with Fuzheng Huayu Capsule and
before treatment), and then Gene Set Enrichment Analysis
(GSEA) was performed in every pathway. Pathways, whose
P-values obtained from GSEA was smaller than 0.05, were
selected. Based on the selected pathways, the expression
pattern similarity between the microarrays of ours and in
thecMapDatabasein everypathwaywascalculatedusing the
KS-test, which was recommended by Li et al. [22].
The progress of KS-test is as follows:
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In the formula above, t is the number of genes in either
the up- or down-regulated gene groups and j is the jth gene
according to the rank of diﬀerential expression. N is the
number of total genes in array, and the position of the jth
gene in the rank ordered whole gene list is V(j).
The result of similarity (KS value) in every pathway
would be either positive or negative (“positive” displays the
similar eﬀects and “negative” displays the reversed eﬀects).
The top 10 reference chemicals which had the most similar
pathway (both positive and negative) numbers were selected
for each analysis.
All the process above was executed in R (Statistical soft-
ware).
2.7. Statistic Analysis. F r o mt h eb l o o dt e s td a t ao fp a t i e n t s
suﬀering liver cirrhosis combining hyperglycemia or dys-
lipidemia, some indexes related with hyperglycemia or dy-
slipidemia were extracted, including fasting blood-glucose
(GLU), postprandial plasma glucose (PPG), glycated hemo-
globin (HbA1c), total cholesterol (T-ch) and total triglyc-
eride (TG). The blood test data were expressed as means
± SD. Comparisons between before treatment and after
treatment were performed by Student’s t-test. The level of
signiﬁcance was set at P<0.05. t-test was executed in R.
3. Results and Discussion
3.1. Diﬀerential Expression and Pathway Enrichment. The
samples from three patients (patients A, B, and C) were,
respectively, analyzed by PBSC method. The microarray
data of patient B showed more diﬀerence expression genes
(4375 up, 3066 down) than patient A (1642 up, 1743 down)
between being treated with Fuzheng Huayu Capsule and
before treatment. In other words, the recipe produced a
greater eﬀect on patient B.
Similarly, patient B showed more pathway changes than
patient A in the pathway enrichment analysis (67 pathways
versus 48 pathways). Many pathways were larger primary
metabolic process; some smaller pathways were presented in
Table 1. In the smaller pathways, the ubiquitin cycle with the
proteincatabolicmetabolismseemedtobeveryimportantin
our result. But so many larger primary metabolic processes
can also contain, suggested that the eﬀects of Fuzheng Huayu
Capsule may be as a whole-regulated mechanism.
Though patient C was treated with placebo, the microar-
ray data also had many diﬀerential expression genes (2297
up, 1723 down). But these genes were in disorder and do
not enrich many eﬀects. Only 4 pathways were enriched
(Table 1).
There were many factors leading to the large diﬀerence
before and after treatment even for placebo, such as the
patients’ situation and nursing care during the process of
treatment. More repeated microarray examples with repeat-
ed experiment would be collected in future to improve the
data unbalance.
3.2. The Top 10 Molecules Had Similar Gene Expression Pat-
tern and with Fuzheng Huayu Capsule. After pathway en-
richment analysis, the similarity search for every pathway
between the microarray data and cMap Database was exe-
cuted. For each patient, top 10 drug molecules in cMap
Database sharing the largest number of signiﬁcantly aﬀected
pathway numbers with Fuzheng Huayu Capsule (patients A
and B) or placebo (patient C) were presented in Table 2.“ + ”
indicates the number of pathways positively correlated; “−”
indicate the number of pathways negatively correlated.4 Evidence-Based Complementary and Alternative Medicine
Table 1: Partial pathway enrichment.
Patient A pathways Patient B pathways Patient C pathways
Ubiquitin cycle Uubiquitin cycle Cellular protein metabolic process
Leukocyte migration Apoptosis Protein metabolic process
Transmembrane receptor protein tyrosine
kinase signaling pathway
Ubiquitin-dependent protein catabolic
process Cellular macromolecule metabolic process
Nitrogen compound metabolic process Regulation of actin polymerization and/or
depolymerization rRNA metabolic process
Regulation of angiogenesis Nucleocytoplasmic transport
Table 2: The top 10 drug molecules aﬀected pathways with Fuzheng Huayu Capsule or placebo.
(a) Patient A
cMap ID Drug molecule Dose Pathway counts
169 Tacrolimus 1uM 22+
383 Cobalt chloride 100uM 21+
144 Chlorpropamide 100uM 20+ 1−
641 Benserazide 10uM 20+
576 Novobiocin 100uM 20−
487 Pirinixic acid 100uM 20−
421 Triﬂuoperazine 10uM 20+
314 Exisulind 50uM 20+
284 Tacrolimus 1uM 20+
268 Genistein 1uM 20+
(b) Patient B
cMap ID Drug molecule Dose Pathway counts
487 Pirinixic acid 100uM 53+
161 Verapamil 10uM 52+
2 Metformin 10uM 52+
419 Chlorpromazine 10uM 49+
49+ Sirolimus 100nM
49+ Dexverapamil 10uM
141 Chlorpropamide 100uM 49+
122 Alpha-estradiol 10nM 49+
457 Tetraethylenepentamine 100uM 47−
124 Mesalazine 100uM 46+
(c) Patient C
cMap ID Drug molecule Dose Pathway counts
608 NU-1025 100uM 4−
418 Haloperidol 10uM 4+
282 Fludrocortisone 1uM 4+
1072 Trichostatin A 1uM 3+
984 Acetylsalicylic acid 100uM 3+
1009 Clozapine 10uM 3+
1017 Fluphenazine 10uM 3+
1024 Haloperidol 10uM 3+
995 Prochlorperazine 10uM 3−
887 Celastrol 3uM 3+Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Predicted eﬀects of Fuzheng Huayu Capsule. There were many drug molecules predicted by our method can reﬂect one part
of eﬀects of the formulae, including anti-hyperglycemic (chlorpropamide, metformin), anti-hyperlipidemic (pirinixic acid), hypotensor
(verapamil, dexverapamil), anti-inﬂammatory, and anti-ﬁbrosis drugs (tacrolimus, sirolimus, and mesalazine), molecules having global
eﬀects (estrogen, genistein).
Almost all drug molecules presented in Tables 2(a) and
2(B) had positive pathways, so these molecules had similar
gene expression pattern and eﬀects with Fuzheng Huayu
Capsule in such pathways. These drug molecules could
be classiﬁed by their eﬀects, including anti-hyperglycemic
(Chlorpropamide, Metformin), anti-hyperlipidemic (Pirin-
ixic acid), hypotensor (Verapamil, Dexverapamil), anti-
inﬂammatory and Anti-ﬁbrosis drugs (Tacrolimus, Sirol-
imus, Mesalazine) and some molecules having global eﬀects
(Estrogen, Genistein). The new eﬀects of Fuzheng Huayu
Capsule was predicted and summarized in Figure 3.
In anti-inﬂammatory and Anti-ﬁbrosis drugs, Tacroli-
mus in Patient A and Sirolimus in Patient B were immuno-
suppressant drugs. Tacrolimus was a calcineurin inhibitor.
Sirolimus inhibits the response to IL-2, and thereby blocks
activation of T- and B-cells. They can also ameliorate ﬁbrosis
[23, 24]. Mesalazine was also an anti-inﬂammatory drug
[25]. These results showed the known eﬀects of Fuzheng
Huayu Capsule.
In Anti-hyperglycemic, Chlorpropamide was the only
molecule positive in both patients A and B. It was a drug
in the sulphonylurea class used to treat type 2 diabetes
mellitus [26]. Sulfonylureas bind to K+ channel on the
cell membrane of pancreatic beta cells, Then depolarization
opens voltage-gated Ca2+ channels. The rise in intracellular
calcium leads to increased fusion of insulin granulae with
the cell membrane, and therefore increased secretion of
(pro)insulin [26]. Metformin was also a drug used to treat
t y p e2d i a b e t e sm e l l i t u s[ 27].
In hypotensive, verapamil and dexverapamil were cal-
cium channel blockers of the phenylalkylamine class. It had
been used in the treatment of hypertension [28]. Calcium
channels were present in the smooth muscle that lines blood
vessels. By relaxing the tone of this smooth muscle, calcium-
channel blockers dilate the blood vessels [28].
In anti-hyperlipidemic, pirinixic acid was a hypolipi-
demic, peroxisome proliferator-activated receptor [29].
There was a special situation about pirinixic acid in our
result. pirinixic acid in patient A was negative to Fuzheng
HuayuCapsule,whileitwaspositiveinpatientB.Thismeans
Fuzheng Huayu Capsule could play a role like pirinixic acid
to reduce blood lipids and play a reversed role to raise blood
lipids. Some other researches had found the bidirectional
regulation eﬀect of TCM [30, 31]; it was an unique feature of
TCM which was rare in western medicine. We also did some
veriﬁcation on the bidirectional regulation eﬀect of Fuzheng
Huayu Capsule in Section 3.4.
In molecules having global eﬀects, genistein was one
of several known isoﬂavones found in leguminous plants,
causing eﬀects in the body similar to those caused by the
hormone estrogen (estradiol). Isoﬂavones and estradiol can
regulate blood glucose [32], blood fat [33], blood pressure
[34],inﬂammation[35]withmanylong-termsystemiceﬀect.
There were also some molecules in Tables 2(a) and 2(b)
that did not have many relationships with the above diseases
(diabetes mellitus, dyslipidemia, hypertension, hepatitis and
liver cirrhosis). Tetraethylenepentamine was negative to
Fuzheng Huayu Capsule in patient B and it was a harmful
substance to people, so this result hinted that tetraethylene-
pentamine would aggravate the illness of patients. Chlor-
promazine in Patient B and triﬂuoperazine in patient A
were typical antipsychotic. Exisulind and novobiocin were
drugs used to treat cancer. But in Table 2(c), the placebo
also shows these eﬀects by some molecules, though the
number of pathways was very small. Haloperidol, clozapine,
ﬂuphenazine, and prochlorperazine were all antipsychotic.
Trichostatin A was an anti-tumor agent. So antipsychotic
and anti-tumor were not the main eﬀects of Fuzheng Huayu
Capsule. This eﬀect might have some other cause. There
might be some bias in examples or the patients may had
some comfort mentality after treatment and then show some
eﬀects of psychotropic drugs.
3.3. The Potential Multiple-Target Molecular Pharmacology
of Fuzheng Huayu Capsule. Integrating all the information6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: potential multiple-target molecular pharmacology of Fuzheng Huayu Capsule. Genistein and estradiol were assigned to long-term
regulation group and other drugs were assigned to short-term regulation group. Ca2+ related eﬀects might have core eﬀects in the molecular
pharmacology of the short-term group.
Table 3: The laboratory parameters of blood glucose and blood lipid.
Laboratory
parameters
Total
patient
number
Improved
patient
number
Normal
value
range
Total
average
before
treatment
Total
average
after
treatment
P value (T
test)
GLU (mmol/L) 17 7 3.89–6.1 7.42 6.52 0.068
PPG (mmol/L) 31 12 3.9–7.8 10.84 8.72 0.025
HbA1c (%) 21 16 4.3–6.5 7.48 5.86 0.00002
T-ch (higher)
(mmol/L) 7 4 2.86–5.98 7.19 6.49 0.383
T-ch (lower)
(mmol/L) 8 7 2.86–5.98 2.66 3.76 0.0207
TG(higher) (mmol/L) 11 7 0.58–1.88 2.61 1.93 0.105
TG (lower) (mmol/L) 7 5 0.58–1.88 0.52 0.94 0.106
above, a mechanism map of Fuzheng Huayu Capsule eﬀects
was built up as follows (Figure 4). The drugs in our results
were divided into two big groups, long-term regulation
group and short-term regulation group. Genistein and estra-
diol were assigned to long-term regulation group, because
they had many sustained eﬀects on our health and we can
get them by daily diet or produce them by ourselves.
Chlorpropamide/metformin, tacrolimus/sirolimus, ver-
apamil/dexverapamil, and Pirinixic acid were all assigned
to short-term regulation group. The Ca2+ related eﬀects
had a core eﬀects in the molecular pharmacology of the
short-term eﬀects of Fuzheng Huayu Capsule. Ca2+ is an
important second messenger in many cell primary metabolic
processes such as inﬂammation, metabolism, apoptosis,
smooth muscle contraction, intracellular movement, nerve
growth, and the immune response.
There was an important point that these small molecules
were selected by eﬀects, not by compound structure. The
PBSC method could ﬁnd molecules having similar eﬀects,
not similar structure. In fact, many molecules in our result
had considerable side eﬀect, but Fuzheng Huayu Capsule do
not have considerable side eﬀect.
Therefore, our result did not means there were some
molecules in Fuzheng Huayu Capsule having similar struc-
ture or drug target with the molecules in our result. They
should only have similar eﬀect on downstream mechanism,
such as Ca2+ related pathway.
3.4. Blood Test Veriﬁcation. To verify our prediction, we
took use of some existing data of blood tests. The data
included360samplesfrom180QiXuXueYuZHENGpatients
in both states of before treatment and being treated with
Fuzheng Huayu Capsule. But these samples were at ﬁrst not
collected to prove the eﬀect of Fuzheng Huayu Capsule on
hyperglycemia or dyslipidemia. So only a part of the patients
were suﬀering hyperglycemia or dyslipidemia, while all the
180 patients were suﬀering liver cirrhosis. The laboratory
values of blood glucose and blood lipid in the data of blood
tests were showed in Table 3.Evidence-Based Complementary and Alternative Medicine 7
In blood glucose tests, 17 patients had higher GLU before
treatment and 7 patients (41%) got back to normal range
after treatment with Fuzheng Huayu Capsule. According to
the treatment, total average GLU of the 17 patients went
downfrom7.42to6.52,and12of31patients(38%)gotback
to normal range. PPG and the total average PPG went down
from 10.84 to 8.72. Moreover, 16 of 21 patients (76%) got
back to normal range of HbA1c and the total average HbA1c
went down from 7.48 to 5.86. There were the signiﬁcant
diﬀerence in data of PPG and HbA1c between before and
after treatment (P<0.05).
In blood lipid tests, 7 patients had higher T-ch than
the normal range, while 8 patients had lower T-ch than
the normal range, and 11 patients had higher TG than the
normal range, while 7 patients had lower T-ch than the
normal range. The average values of all sets of patients
tended to normal after treatment. May be it was lack of
samples, the data between before and after treatment did
not have signiﬁcant diﬀerence except that lower T-ch went
up. Interestly, not only the higher T-ch and TG were down
regulated, but also the lower T-ch and TG were up regulated
by Fuzheng Huayu Capsule, which may be a characteristic of
herbal formulae with multi-compounds.
Previous study also reported that Fuzheng Huayu had
comprehensive eﬀectonpatientssuﬀeringliverﬁbrosisalong
with Diabetes mellitus [36]. These results suggested that
Fuzheng Huayu Capsule could really relieve the patients
suﬀering liver cirrhosis combined with diabetes mellitus and
might have biphasic regulation eﬀects on dyslipidemia.
Scince the research was to mainly explore a method
to predict new eﬀects of Fuzheng Huayu Capsule through
integrat the information of ZHENG, herbal formula, and
diseases, the experimental examples were not very abundant.
We would carry out studies on large samples in future.
4. Conclusion
We introduced a high-throughput gene microarrays-based
method (PBSC) to predict the potential eﬀects of Fuzheng
Huayu Capsule, a Chinese herbal formula on liver cir-
rhosis with QiXuXueYu ZHENG. The predicted results
showed that the comprehensive eﬀects of Fuzheng Huayu
Capsule might be including Anti-hyperglycemic, anti-
hyperlipidemic, hypotensive and anti-inﬂammatory, and
Anti-ﬁbrosis drugs. To verify our prediction, we had also
taken the blood tests and got the eﬀectiveness of Fuzheng
Huayu Capsule on liver cirrhosis combined with diabetes
mellitus or dyslipidemia. Further researches must get more
samples to conﬁrm the potential eﬀects of Fuzheng Huayu
Capsule.
Our research results suggested that the PBSC method
is eﬀective to ﬁnd small molecules which had similar gene
expression patterns and eﬀects with herbal formulae and
oﬀer invaluable information for predicting new treatment
application of herbal formulae.
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